# The Mediterranean Sea on the Bench: Unveiling the Marine Invertebrate Sidnyum elegans as a Source of Novel Promising Therapeutic Tools Against Triple-Negative Breast Cancer

**Authors:** Marcello Casertano, Camilla Esposito, Ivana Bello, Martina Barile, Luana Izzo, Emma Mitidieri, Raffaella Sorrentino, Marialuisa Menna, Elisabetta Panza, Concetta Imperatore, Roberta d’Emmanuele di Villa Bianca

PMC · DOI: 10.3390/md23050195 · Marine Drugs · 2025-04-29

## TL;DR

This study explores a marine invertebrate from the Mediterranean Sea as a potential source of new treatments for triple-negative breast cancer.

## Contribution

The study identifies and characterizes a novel bioactive fraction from Sidnyum elegans with anti-cancer properties.

## Key findings

- SEB-5 fraction significantly reduced cell proliferation and induced apoptosis in MDA-MB-231 cells.
- SEB-5 arrested cells in the G0/G1 phase and reduced the expression of cell cycle-related genes.
- SEB-5 showed antimetastatic potential by inhibiting cell migration in a wound-healing assay.

## Abstract

This study aims to unveil the marine invertebrate Sidnyum elegans, a Mediterranean ascidian, as a natural resource for the early development of new treatments for triple-negative breast cancer (TNBC). Nine different fractions obtained via medium-pressure liquid chromatography (MPLC) of the butanol-soluble material of the ascidian were evaluated in proliferating MDA-MB-231 cells in a range of 10–50 µg/mL. Among them, the SEB-5 fraction was found to be the most effective in reducing cell proliferation and concomitantly inducing apoptosis, revealed via MTT assay and FACS analysis using Annexin V/PI dual staining. Furthermore, we investigated the effect of this fraction on cell cycle phases, revealing that SEB-5 can arrest the cells in the G0/G1 phase. This latter effect was then confirmed via transcriptomic analysis, showing that treatment with SEB-5 reduced the expression of cyclinB1, CDC25a, and CDK1. Finally, to evaluate the potential antimetastatic effect of SEB-5, a wound-healing assay was performed showing the ability of SEB-5 to reduce MDA-MB-231 cell migration. The chemical characterization of SEB-5 components was performed using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS/MS) and nuclear magnetic resonance (NMR) spectroscopy. This analysis revealed the presence of a terpenoid and polyketide-like compounds, including the alkyl sulfate 1 and phosphoeleganin 2, along with three novel phosphoeleganin-related products 3–5.

## Linked entities

- **Genes:** CycB (Cyclin B) [NCBI Gene 37618], CDC25A (cell division cycle 25A) [NCBI Gene 993], CDK1 (cyclin dependent kinase 1) [NCBI Gene 983]
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, CDC25A (cell division cycle 25A) [NCBI Gene 993] {aka CDC25A2}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}
- **Diseases:** TNBC (MESH:D064726)
- **Chemicals:** MTT (MESH:C070243), SEB-5 (-), polyketide (MESH:D061065), butanol (MESH:D000440), phosphoeleganin (MESH:C000610612), PI (MESH:D010716), terpenoid (MESH:D013729)
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12112827/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12112827/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12112827/full.md

---
Source: https://tomesphere.com/paper/PMC12112827